Download PDF
Thromb Haemost 1990; 64(03): 407-411
DOI: 10.1055/s-0038-1647328
Original Article
Schattauer GmbH Stuttgart

Concomitant Secretion by A431 Cells of Tissue Plasminogen Activator and a Specific Inhibitor Masks EGF Modulation of tPA Activity

F George
*   The Hematology Laboratory, Faculty of Pharmacy
,
N Pourreau-Schneider
**   The C.N.R.S. URA 1175,North Medical School, Marseille, France
,
B Boutiere
*   The Hematology Laboratory, Faculty of Pharmacy
,
D Arnoux
*   The Hematology Laboratory, Faculty of Pharmacy
,
B Boutiére
*   The Hematology Laboratory, Faculty of Pharmacy
,
Y Berthois
**   The C.N.R.S. URA 1175,North Medical School, Marseille, France
,
P M Martin
**   The C.N.R.S. URA 1175,North Medical School, Marseille, France
,
J Sampol
*   The Hematology Laboratory, Faculty of Pharmacy
› Author Affiliations
Further Information

Publication History

Received 15 October 1989

Accepted after revision 08 June 1990

Publication Date:
25 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

It has previously been reported that EGF enhances uPA but not tPA in the A431 squamous carcinoma cell line. To determine whether the absence of tPA modulation by EGF reflected steady levels or the action of an anti-activator, we assayed tPA, PAI-1 and tPA/PAI-1 complexes by zymography and immunological assays. Under conditions in which EGF had no effect on tPA activity, tPA antigen paradoxically increased with a concomitant rise of tPA/PAI-1 complexes. This indicated that tPA was rapidly inactivated through the formation of a complex, immunologically and electrophoretically related to tPA/PAI-1. tPA antigen and tPA/PAI-1 complexes were modulated by EGF in a time and concentration dependent manner. PAI-1 antigen was secreted into A431 medium (CM) after a lag phase of 16 h in both control andEGF-treated cultures. Evidence is presented here that two forms ofPAI-1 are present in A431 CM: an inactive form and an active form which neutralizes the tPA secreted, masking its enhancement by EGF infunctional assays.

 

  • References

  • 1 van Mourik JA, Lawrence DA, Loskutoff DS. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 1984; 259: 14914-14921
    PubMedGoogle Scholar
  • 2 Astedt B, Lecander I, Brodin T, Lundblad A, Low K. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb Haemostas 1985; 53: 122-125
    PubMedGoogle Scholar
  • 3 Scott RW, Baker JB. Purification of human protease nexin. J Biol Chem 1983; 258: 10439-10444
    PubMedGoogle Scholar
  • 4 Blasi R, Stoppelli MP, Cubellis MV. The receptor for urokinaseplasminogen activator. J Cell Biochem 1986; 32: 179-186
    CrossrefPubMedGoogle Scholar
  • 5 Saksela O, Rifkin DB. Cell-associated plasminogen activation: Regulation and physiological functions. Annu Rev Cell Biol 1988; 4: 93-126
    CrossrefPubMedGoogle Scholar
  • 6 DanO K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266
    PubMedGoogle Scholar
  • 7 Hart DA, Rehemtulla A. Plasminogen activators and their inhibitors: Regulators of extracellular proteolysis and cell function. Comp Biochem Physiol 1988; 908: 691-708
    PubMedGoogle Scholar
  • 8 Laiho M, Keski-Oja J. Growth factors in the regulation of pericellular proteolysis: A review. Cancer Res 1989; 49: 2533-2553
    PubMedGoogle Scholar
  • 9 Quigley JP. Phorbol ester-induced morphological changes in transformed chick fibroblasts: Evidence for direct catalytic involvement of plasminogen activator. Cell 1979; 17: 131-141
    CrossrefPubMedGoogle Scholar
  • 10 Gelehrter TD, Barouski-Miller PA, Coleman PL, Cwikel BJ. Hormonal regulation of plasminogen activator in rat hepatoma cells. Mol Cell Biochem 1983; 53/54: 11-21
    PubMedGoogle Scholar
  • 11 Andreasen PA, Christensen TH, Nielsen LS, Huang JY, Dane K. Hormonal regulation of extracellular plasminogen activators and M. 54,000 inhibitor in neoplastic cell lines, studied with monoclonal antibodies. Mol Cell Endocrinol 1986; 45: 137-147
    CrossrefPubMedGoogle Scholar
  • 12 Pourreau-schneider N, Delori P, BoutiEre B, Arnoux D, George E, Sampol J, Martin PM. Modulation of plasminogen activator systems by matrix components in two breast cancer cell lines: MCF-7 and MDA-MB-231. J Natl Cancer Inst 1989; 8l: 259-266
    PubMedGoogle Scholar
  • 13 NiedbalaE MJ, Sartorelli AC. Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix. Cancer Res 1989; 49: 3302-3309
    PubMedGoogle Scholar
  • 14 Mullins DE, Rohrlich ST. The role of proteinases in cellular invasiveness. Biochim Biophys Acta 1983; 695: 177-214
    PubMedGoogle Scholar
  • 15 Tiyggvason K, Hoyhtya M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 1987; 907: l9l-217
    PubMedGoogle Scholar
  • 16 Haigler H, Ash JE, Singer SJ, Cohen S. Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431. Proc Natl Acad Sci USA 1978; 74: 565-569
    PubMedGoogle Scholar
  • 17 Gross JL, Kruff MN, Rifkin DB, Lane MD. Down-regulation of epidermal growth factor receptor correlates with plasminogen activator activity in human A43l epidermoid carcinoma cells. Proc Natl Acad Sci USA 1983; 80: 2276-2280
    CrossrefPubMedGoogle Scholar
  • 18 Corti A, Nollig ML, Soffientini A, Cassani G. Purification and characterization of single chain urokinase-type plasminogen activator (pro-urokinase) from human A43l cells. Thromb Haemostas 1986; 56: 219-224
    PubMedGoogle Scholar
  • 19 Stoppelli MP, Thcchetti C, Cubellis MV, Corti A, Hearing VJ, Cassani G, Appella E, Blasi E. Autocrine saturation of pro-urokinase receptors on human A43l cells. Cell 1986; 45: 675-684
    CrossrefPubMedGoogle Scholar
  • 20 Kessler TL, Markus G. Modulation of urokinase induction by EGF and TPA in ,4.431 cells. Proc Am Assoc Cancer Res 1988; 29-48
    PubMedGoogle Scholar
  • 21 Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Park WP. In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973; 5l: 1417-1423
    PubMedGoogle Scholar
  • 22 Hinegardner RT. An improved fluorometric assay for DNA. Anal Biochem 1971; 39: 197-201
    CrossrefPubMedGoogle Scholar
  • 23 Laemmli UK. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 24 Granelli-Piperno A, Reich E. A study of proteases and proteaseinhibitor complexes in biological fluids. J Exp Med 1978; 148: 223-234
    CrossrefPubMedGoogle Scholar
  • 25 Loskutoff DJ, van Mourick JA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 1983; 80: 2956-2960
    CrossrefPubMedGoogle Scholar
  • 26 Angles-Cano E, Boutidre B, Arnoux D, Masson C, Contant G, Benchimol P, Sampol J. Release pattern of the vascular plasminogen activator and its inhibitor in human postvenous occlusion plasma as assessed by a spectrophotometric solid-phase fibrin-tPA activity assay. Thromb Haemostas 1987; 58: 843-849
    PubMedGoogle Scholar
  • 27 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemostas 1985; 54: 684-687
    PubMedGoogle Scholar
  • 28 Declerck PJ, Alessi MC, Verstreken M, Krulthof EK O, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1-(PAI-l) in biological fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 7l: 220-225
    PubMedGoogle Scholar
  • 29 Amiral J, Plassart V, Grosley M, Mimilla R, Contant G, Guyader AM. Measurement of tPA and tPA-PAI-L complexes by ELISA, using monoclonal antibodies: Clinical relevance. Thromb Res 1988; suppl (Suppl. 08) 99-113
    PubMedGoogle Scholar
  • 30 Vassalli JD, Belin D. Amiloride selectively inhibits the urokinasetype plasminogen activator. FEBS Lett 1987; 214: 187-191
    CrossrefPubMedGoogle Scholar
  • 31 Saksela O, Vaheri A, Schleuning WD, Mignatti P, Barlati S. Plasminogen activators, activation inhibitors and alpha2-macroglobu- Iin produced by cultured normal and malignant human cells. Int J Cancer 1984; 33: 609-616
    CrossrefPubMedGoogle Scholar
  • 32 Galway AB, Oikaw M, Ny T, Hsueh AJ W. Epidermal growth factor stimulates tissue plasminogen activator activity and messenger ribonucleic acid levels in cultured rat granulosa cells: Mediation by pathways independent of protein kinases-A and -C. Endocrinology 1989; 125: 126-135
    CrossrefPubMedGoogle Scholar
  • 33 Dubeau L, Jones PA, Rideout WM III, Lang WE. Differential regulation of plasminogen activators by epidermal growth factor in normal and neoplastic human urothelium. Cancer Res 1988; 48: 5552-5556
    PubMedGoogle Scholar
  • 34 Roblin RO, Young PL, Bell TE. Concomitant secretion by transformed SVWI38-VA13-2RA cells of plasminogen activator(s) and substance(s) which prevent their detection. BBRC 1978; 82: 165-172
    PubMedGoogle Scholar
  • 35 Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 1985; 823: 35-65
    PubMedGoogle Scholar
  • 36 Levin EG. Latent tissue plasminogen activator produced by human endothelial cells in culture: Evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci USA 1983; 80: 6804-6808
    CrossrefPubMedGoogle Scholar
  • 37 Andreasen PA, Nielsen LS, Kristensen P, Grgndahl-Hansen J, Skriver L, Dang K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem 1986; 261: 7644-7651
    PubMedGoogle Scholar
  • 38 Vassalli JD, Dayer JM, Wohlwend A, Belin D. Concomitant secretion of pro-urokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med 1984; 159: 1653-1668
    CrossrefPubMedGoogle Scholar
  • 39 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator: Role of fibrin. J Biol Chem 1982; 257: 2912-2919
    PubMedGoogle Scholar
  • 40 Kooistra I, Sprengers ED, van Hinsbergh VW M. Rapid inactivation of the plasminogen activator inhibitor upon secretion from cultured human endothelial cells. Biochem J 1986; 239: 497-503
    CrossrefPubMedGoogle Scholar
  • 41 Wagner OR, Binder B. Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line. J Biol Chem 1986; 261: 14474-14481
    PubMedGoogle Scholar
  • 42 Kruithof EK O, Vassalli J-D, Schleuning W-D, Mattaliano RJ. Purification and characteization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem 1986; 261: 11207-11213
    PubMedGoogle Scholar
  • 43 Mimuro J, Schleef RR, Loskutoff DJ. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type L plasminogen activator inhibitor. Blood 1987; 70: 721-728
    PubMedGoogle Scholar
  • 44 Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-11587
    PubMedGoogle Scholar
  • 45 Levin EG. Quantitation and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells. Blood 1986; 67: 1309-1313
    PubMedGoogle Scholar
  • 46 Levin EG, Santell L. Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells. Blood 1987; 70: 1090-1098
    PubMedGoogle Scholar
  • 47 Wun T-C, Palmier MO, Siegel NR, Smith CE. Affinity purification of active plasminogen activator inhibitor-L (PAI-l) using immobilized anhydrourokinase. Demonstration of the binding, stabilization, and activation of PAI-1 by vitronectin. J Biol Chem 1989 264. 7862-7868
    PubMedGoogle Scholar
  • 48 Lucore CL, Fujii S, Wun T-C, Sobel BE, Billadello JJ. Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor. J Biol Chem 1988; 263: 15845-15848
    CrossrefPubMedGoogle Scholar
  • 49 Bergonzelli GE, Kruithof EK O. Stimulation autocrine de inhibiteur 1 des activateurs du plasminogBne dans les cellules d'h6patome humain Hep G2. Societe, Frangaise d'Hematologie, Congres Biologie Moleculaire et Hemostase, Villar-sur-Ollon 1990 abstract 29
    PubMedGoogle Scholar
  • 50 Nielsen LS, Andreasen PA, Grendahl-Hanson J, Huang J-Y, Christensen R, Dang K. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells. Inhibitor neutralization and one-step affinity purification. Thromb Haemostas 1986; 55: 206-212
    PubMedGoogle Scholar
  • 51 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387
    PubMedGoogle Scholar